Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
BACKGROUND
Women with BRCA1 mutations develop breast cancer with similar pathologic features to sporadic triple negative (TN) breast cancer, a subtype associated with early disease relapse and poor outcome. The clinical outcome of women with and without BRCA1 mutations who had TN breast cancer treated with conventional chemotherapy were compared.


METHODS
Women with stage I to III TN breast cancer who had BRCA1 testing within 36 months of diagnosis and received alkylating chemotherapy were identified from clinical databases and a Specialized Program of Research Excellence (SPORE) specimen bank. BRCA2 mutation carriers were excluded, resulting in a study cohort of 46 BRCA1 carriers and 71 noncarriers. Sites of metastasis, relapse rates, and survival were compared among carriers and noncarriers. The median follow-up was 75 months.


RESULTS
BRCA1 carriers were younger at diagnosis (P < .001) and had smaller tumors (P = .03) than noncarriers. Freedom from distant metastasis at 5 years was 76% for carriers and 70% for noncarriers (hazard ratio [HR] 0.79, P = .5). Sites of distant recurrence did not differ significantly (P = .15), although BRCA1 carriers had a propensity for brain relapse (58% vs 24%, P = .06). Overall survival at 5 years was 82% for carriers and 74% for noncarriers (HR 0.64, P = .25). Adjusting for age and stage, BRCA1 mutation status was not an independent predictor of survival (HR 0.73, P = .48).


CONCLUSIONS
BRCA1 mutation carriers with TN disease had similar survival rates to noncarriers when treated with alkylating chemotherapy. Women with BRCA1-related breast cancer may benefit from novel therapies that target DNA repair, and further study is needed to identify sporadic TN breast cancers with a BRCA-deficient phenotype.
Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Larissa J
LJ
Lee
Brian
B
Alexander
Stuart J
SJ
Schnitt
Amy
A
Comander
Bridget
B
Gallagher
Judy E
JE
Garber
Nadine
N
Tung
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005260:Female; D019398:Genes, BRCA1; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
J Clin Oncol. 2010 Jan 20;28(3):375-9
20008645
BMC Cancer. 2005 Jul 04;5:70
15996267
Am J Surg Pathol. 2009 Jul;33(7):1093-7
19390427
J Clin Oncol. 1998 May;16(5):1642-9
9586873
J Clin Oncol. 2006 Dec 20;24(36):5652-7
17116942
J Clin Oncol. 2002 May 1;20(9):2310-8
11981002
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
Breast Cancer Res. 2006;8(4):R34
16846532
Cancer. 2007 Jan 1;109(1):25-32
17146782
Breast Cancer Res. 2004;6(1):R8-R17
14680495
J Clin Oncol. 2000 Dec 15;18(24):4045-52
11118465
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
N Engl J Med. 2007 Jul 12;357(2):115-23
17625123
Lancet. 2010 Jul 24;376(9737):235-44
20609467
Ann Oncol. 2006 Mar;17(3):391-400
16322115
N Engl J Med. 2009 Jul 9;361(2):123-34
19553641
Oncogene. 2006 Sep 25;25(43):5846-53
16998499
Am J Surg Pathol. 2006 Sep;30(9):1097-104
16931954
Breast. 2007 Jun;16(3):280-92
17257844
Nature. 2000 Aug 17;406(6797):747-52
10963602
J Natl Cancer Inst. 1999 Dec 15;91(24):2112-7
10601383
Ann Surg Oncol. 2004 Feb;11(2):157-64
14761918
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
15328174
J Clin Oncol. 2000 Dec 15;18(24):4053-9
11118466
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
17671126
Clin Cancer Res. 2008 Dec 15;14(24):8010-8
19088017
J Clin Oncol. 2010 Jul 10;28(20):3271-7
20498394
Lancet. 1997 May 24;349(9064):1505-10
9167459
Cancer. 2008 Nov 15;113(10):2638-45
18833576
Breast Cancer Res Treat. 2009 May;115(2):359-63
18649131
Nat Rev Cancer. 2004 Oct;4(10):814-9
15510162
Oncogene. 2007 Mar 29;26(14):2126-32
17016441
Clin Cancer Res. 2009 Apr 1;15(7):2302-10
19318481
BMC Cancer. 2007 Jul 24;7:134
17650314
Clin Cancer Res. 2008 Mar 1;14(5):1368-76
18316557
J Clin Oncol. 2008 Sep 10;26(26):4282-8
18779615
J Clin Oncol. 2008 Mar 10;26(8):1275-81
18250347